Ultragenyx Pharmaceutical, Inc. RARE 深 滬
等待開盤 10-28 09:30:00 美东时间
16.75
+0.670
+4.17%
華盛通- 最 高16.96
- 今 開16.05
- 成交量 494.45万股
- 最 低 15.88
- 昨 收 16.08
- 總市值 16.51亿
- 52周最高 39.8899
- 市盈率 靜 --
- 換手率 5.02%
- 52周最低 12.73
- 委 比 -1.81%
- 總股本 9858.89万
- 歷史最高 179.647
- 量 比 1.82
- 振 幅 6.72%
- 歷史最低 12.73
- 每 手 1
- 風險率 6.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅279.75%！Jones Trading维持Contineum Therapeutics(CTNM)"买入"评级，目标价上调至30美元
今日重点评级关注：Jones Trading：维持Contineum Therapeutics"买入"评级，目标价从24美元升至30美元；StoneX：维持Forum Markets"投机性买入"评级，目标价从9美元升至12美元
10-16 12:30
UBS Initiates Coverage On Ultragenyx Pharmaceutical with Neutral Rating, Announces Price Target of $16
UBS analyst Joon Lee initiates coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral rating and announces Price Target of $16.
10-16 05:31
Ultragenyx to sell FDA priority review voucher for $210M
Ultragenyx Pharmaceutical (RARE) traded higher on Wednesday after announcing a $210M deal to sell a priority review voucher received in connection with the FDA approval of its rare disease therapy Gen...
10-07 22:09
Ultragenyx Launches 10-Year Gene Therapy Monitoring Program for MPS IIIA
Ultragenyx Pharmaceutical, Inc. ($RARE) announced an update on their ongoing cl...
10-03 00:31
Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)
Ultragenyx announced that the European Medicines Agency (EMA) has validated its Marketing Authorisation Application (MAA) for rebisufligene etisparvovec, a gene therapy for treating mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome Type A. EMA validation indicates the application is sufficiently complete for scientific review, though it does not guarantee approval. MPS IIIA is a rare, fatal genetic disorder with limite...
10-02 06:00
美股大行评级 | 麦当劳目标价遭下调至320美元！现价仍有近3成上涨空间；戴尔、迈威尔、微软齐获机构看好
今日重点评级关注：HC Wainwright & Co.：维持Gossamer Bio"买入"评级，目标价从2美元升至90美元；巴克莱：维持Ultragenyx Pharmaceutical"超配"评级，目标价从32美元升至35美元
09-22 16:25
美股大行评级 | 奈飞遭看淡至57美元！现价仍有两成下行空间；Xenon制药遭多家机构降目标价，最低看至46美元
今日重点评级关注：康托·菲茨杰拉德：维持Abeona Therapeutics"超配"评级，目标价从28美元升至30美元；HC Wainwright & Co.：维持Oculis Holding"买入"评级，目标价从26美元升至39美元
09-21 16:25
美股牛股 | 电力股齐升，Generac暴升18%，获亚马逊大单+入股，Vicor升逾17%；RARE升逾12%，获罕见儿科PRV
电力股齐升，Generac暴升18%，获亚马逊大单+入股，Vicor升逾17%，FCEL升逾14%；RARE升逾12%，获罕见儿科PRV>>
09-18 18:45
Ultragenyx Pharmaceutical shares are trading higher after the company announced the FDA approval of FAYUVI for treatment of pediatric patients with mucopolysaccharidosis type IIIA.
Ultragenyx Pharmaceutical shares are trading higher after the company announced the FDA approval of FAYUVI for treatment of pediatric patients with mucopolysaccharidosis type IIIA.
09-18 03:58
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
Ultragenyx Pharmaceutical Inc. announced the U.S. FDA approval of FAYUVI™ (rebisufligene etisparvovec-hopf) for the treatment of pediatric patients with Sanfilippo syndrome Type A, a progressive and fatal neurodegenerative disease. FAYUVI is the first-ever FDA-approved treatment for this condition and the second gene therapy approval for Ultragenyx. The therapy is expected to be available to Qualified Treatment Centers within 30-60 days. Clinical...
09-17 19:48
